Abstract
Recent studies report a possible mortality benefit of treatment with long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.
Original language | English |
---|---|
Article number | A2251 |
Number of pages | 1 |
Journal | American Journal of Respiratory and Critical Care Medicine |
Volume | 203 |
Early online date | 19 May 2021 |
DOIs | |
Publication status | Published - 2021 |
Event | ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/ |